Calmiox

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Calmiox

Property Description
Active ingredient Hydrocortisone
Form Cream, Topical Aerosol Foam
Pharmacological class Low-Potency Topical Corticosteroid
General purpose Local Symptomatic Relief (Itching/Irritation)
Origin Synthetic (Analogue of Natural Cortisol)

What Type of Medicine is Calmiox? (Identity and Pharmacological Class)

Calmiox is a single-ingredient medicine intended exclusively for topical use, classified pharmacologically as a corticosteroid. Its primary objective is to provide effective local symptomatic relief from discomfort associated with minor skin irritations and itching.

The preparation's active ingredient is Hydrocortisone, which defines it as a low-potency topical steroid within the broader glucocorticoid class. Pharmacological studies have clinically recognized Hydrocortisone for its established anti-inflammatory and immunosuppressive properties, ensuring the medication helps ease skin discomfort by calming the body’s temporary local response to irritants, such as common insect bites.


Composition and Forms: The Hydrocortisone Base (Composition and Origin)

The core therapeutic component is Hydrocortisone, a substance chemically identical to Cortisol, the naturally occurring steroid hormone secreted by the human body. Although its origin is natural, the ingredient used in Calmiox is manufactured as a synthetic form to ensure consistency and standardization for its topical use.

Calmiox is available in different pharmaceutical preparations, including a Cream and a specialized Topical Aerosol Foam. This provides flexibility in the dosage forms for the cutaneous route of administration, allowing the patient to select the base (cream or foam) best suited for the affected area requiring local symptomatic relief.

Regulatory References

  1. Hydrocortisone Drug Information | MedlinePlus

What side effects are possible with Calmiox?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety-related information for Calmiox (Aceclofenac), strictly based on governmental regulatory documents.

Serious Adverse Reactions and Key Safety Warnings

Regulatory authorities mandate warnings regarding two major, potentially life-threatening risks associated with this medicine:

  • Cardiovascular Thrombotic Events: An increased risk of serious events such as heart attack (myocardial infarction) or stroke may occur, which can happen early in treatment and may increase with the duration of use and higher doses.
  • Gastrointestinal Risk: There is an increased risk of serious gastrointestinal bleeding, ulceration, or perforation of the stomach or intestines. These events can be fatal and may occur without warning symptoms.

Common Adverse Reactions

The most frequently reported side effects are generally related to the gastrointestinal system. These are typically classified as Common (occurring in at least 1 out of 100 patients) and include:

  • Dyspepsia (upset stomach or indigestion)
  • Abdominal pain
  • Nausea
  • Diarrhea
  • Increases in liver enzymes (detected via blood tests)

Contraindications and Safety Restrictions

Calmiox is contraindicated and should not be used in specific patient populations or circumstances:

  • For treating pain immediately before or after Coronary Artery Bypass Graft (CABG) surgery.
  • In patients with a known history of severe allergic reactions (such as asthma, hives, or anaphylaxis) after taking aspirin or other similar medicines.
  • During the third trimester of pregnancy due to the documented risk of harm to the fetus.
  • In patients with active gastrointestinal bleeding or ulceration.

Overdose and Emergency Response

Overdose and When to Seek Help

Overuse of topical corticosteroids like Calmiox, especially on large surface areas, for prolonged periods, or under occlusive dressings (including diapers), may result in systemic effects and overdose presentations. The primary risk is the inhibition of the Hypothalamic-Pituitary-Adrenal (HPA) axis due to significant absorption of the active ingredient into the bloodstream.

Documented Overdose Presentations

System Affected Potential Manifestations
Endocrine System Adrenal suppression, which can lead to hypoadrenalism; Cushing's syndrome; Growth retardation (especially in children).
Symptoms Malaise, fatigue, muscle/joint pain, headache, nausea, and vomiting, or potentially severe, life-threatening conditions in cases of severe hypoadrenalism.

When to Seek Immediate Medical Help

Immediate medical attention is necessary if Calmiox is accidentally swallowed. You should also call for professional medical advice or seek emergency care if you suspect systemic side effects, such as unexplained weight gain, puffiness in the face, vision problems, or signs of severe fatigue or malaise, particularly after extended or high-exposure use. Children are at an increased risk for systemic effects, and any sign of adrenal suppression or growth concerns warrants urgent medical evaluation.

Therapeutic Uses of Calmiox

What Calmiox Treats: Main Uses and Benefits

Calmiox is a low-potency topical corticosteroid, used to provide supportive local symptomatic relief in dermatological contexts. It is commonly used to help address symptoms related to inflammatory or irritative states, contributing to easing the overall symptom load. Topical hydrocortisone is commonly used to help manage the redness, swelling, itching, and discomfort of various skin conditions.

Symptom Relief and Application Contexts

This medication may assist with managing symptoms like persistent itching (pruritus), localized burning, general skin irritation, acute redness (erythema), and minor localized swelling (edema). Calmiox is relevant in clinical scenarios marked by episodic, external triggers, such as temporary allergic contact dermatitis, common reactions to insect bites and stings, and seasonal issues like heat rash. It is relevant for managing symptoms that interfere with daily comfort, and may assist with maintaining functional stability when discomfort intensifies.

Quick Fact: Relief for Itching and Minor Inflammation Calmiox is applied in contexts where short-term symptom management is appropriate for conditions characterized by episodic or fluctuating symptoms related to physical discomfort and localized inflammatory processes.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility and Contraindications for Calmiox

Calmiox, a topical hydrocortisone preparation, is governed by strict regulatory eligibility rules defining its appropriate use. It is contraindicated for any patient with a known history of hypersensitivity to hydrocortisone or any of the product’s non-medicinal ingredients.

Use is prohibited on areas of skin affected by untreated infections, including viral infections (such as herpes simplex or varicella), fungal infections, or bacterial infections, as corticosteroids can mask symptoms or worsen the condition. Local conditions such as acne, acne rosacea, perioral dermatitis, or ulcers also prohibit application.

Population Group Eligibility Status (Regulatory Basis)
Children under 12 Use not recommended without medical supervision due to higher risk of systemic absorption (HPA axis suppression).
Pregnancy/Lactation Restricted Use: Only if potential benefit justifies risk to fetus/infant. Application should be minimal in quantity and duration.
Systemic Conditions Use with Caution: Patients with diabetes, Cushing's Syndrome, or severe hepatic impairment require close monitoring.

The application area should not be covered by an occlusive dressing (including diapers on infants) unless explicitly directed by a healthcare provider, as this significantly increases the risk of systemic absorption and associated adverse effects.

What should I know about interactions with other medicines?

Calmiox Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Calmiox (topical hydrocortisone) as established in government regulatory sources. Due to its classification as a low-potency topical corticosteroid intended for local use, the risk of clinically significant systemic drug-drug interactions is considered low under normal conditions.


Documented Interaction Categories

Interaction Type Practical Implication based on Labeling
Local Pharmacodynamic Avoid simultaneous use with other topical preparations on the same skin area to prevent additive effects or altered absorption.
Concomitant Steroids Use alongside other topical or systemic corticosteroids may increase the overall risk of systemic side effects, such as adrenal suppression, if significant absorption occurs.
Diagnostic Interference Systemic absorption of the medicine may interfere with diagnostic tests of adrenal function and potentially alter blood or urine sugar concentrations.

Interaction-Related Cautions

Regulatory information notes two key population-specific cautions. The risk of adverse effects from systemic absorption is greater in children due to their higher skin surface area to body weight ratio. Additionally, patients with diabetes should be aware that the use of this medication may potentially alter their control of blood sugar levels, which is a pharmacodynamic effect related to absorbed hydrocortisone.

Mechanism of Action

Calmiox contains hydrocortisone, a synthetic glucocorticoid. Its primary biological target is the cytosolic Glucocorticoid Receptor (GR), to which it acts as an agonist. Upon binding, the activated drug-receptor complex translocates into the cell nucleus, where it functions as a transcription factor, modulating gene expression. This genomic mechanism primarily involves the complex binding to Glucocorticoid Response Elements (GREs) in the promoter region of target genes, leading to the upregulation of anti-inflammatory proteins, notably Annexin A1 (Lipocortin).

Annexin A1 then acts as an indirect inhibitor of Phospholipase A2 ( PLA2) activity, thereby restricting the cleavage of membrane phospholipids and the subsequent release of arachidonic acid. This limits the downstream biosynthesis of pro-inflammatory eicosanoids, such as prostaglandins and leukotrienes. Additionally, the complex suppresses the transcription of various inflammatory mediator genes (e.g., cytokines, chemokines) via negative gene regulation, often by direct protein-protein interaction with transcription factors like NF-kappa B. These molecular and intracellular pathways ultimately result in a system-level physiological consequence of vasoconstriction and reduced localized cell migration of leukocytes and macrophages to the target tissue.

Dosage and Administration Information

How to Use Calmiox: Official Administration Guidelines

Calmiox is a topical medication whose official use is strictly defined by regulatory documents, emphasizing correct application, frequency, and duration of treatment.


Approved Administration

The preparation is approved for the topical or cutaneous route of administration only. It is to be used strictly for external skin application. Calmiox is available in different pharmaceutical presentations, including a Cream and a Topical Aerosol Foam.


Standard Dosing and Application Rules

Dosing Parameter Official Instruction (Based on Regulatory Labeling)
Application Amount Apply a thin film of the preparation to the affected skin area.
Frequency Apply two to four times daily, as directed by a healthcare professional, or up to four times daily for non-prescription products.
Duration Constraint Continuous use should typically be limited to a maximum of 7 days for non-prescription preparations, or two weeks before reassessment.

Key Procedural Instructions

  1. Hand Hygiene: Hands should be thoroughly washed before and after applying the medication (unless the hands are the area being treated).
  2. Application: Gently rub the thin film in until the medicine disappears (where applicable).
  3. Avoid Occlusion: The treated skin area must not be bandaged or covered with an airtight or occlusive dressing, unless specifically instructed by a healthcare provider.
  4. Area Avoidance: Do not apply to the eyes, mouth, or other mucous membranes. The preparation is not to be swallowed.

Population-Specific Rules

  • Pediatric Use: Administration to children should be limited to the least amount compatible with effective treatment. Chronic therapy may interfere with growth. Non-prescription products are generally not labeled for use in children under 2 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Calmiox

This section describes the types of research that have explored the active ingredient in Calmiox, the study outcomes that were evaluated, and what specific questions remain unaddressed in the research. This information is intended to provide context about the evidence and is not medical advice.

Evidence for Temporary Symptomatic Relief of Minor Skin Itching/Irritation

Research has explored the active ingredient in Calmiox and its evaluation through short-term clinical trials. These studies, often designed as Randomized Controlled Trials (RCTs), were conducted during periods of increased symptom activity in people experiencing localized, mild-to-moderate skin irritations. Researchers examined outcomes related to physical discomfort, measuring changes in patient-reported itch intensity and documenting visible changes in the skin, such as redness. Some trials described patterns where measurements of itch scores varied over a few days of application.

Evidence for Temporary Symptomatic Relief of Mild Skin Allergies

The evidence base for the active ingredient's evaluation in mild, acute skin allergies, such as localized allergic contact dermatitis, comes from controlled trials and reviews that synthesize data on low-potency topical steroids. These studies monitored patient-reported outcomes describing perceived discomfort and measured the time it took for changes in visible signs of skin inflammation to be observed. Findings describe patterns observed in the studies where measured changes in itching were reported during the short periods of application.

Long-Term Studies and Follow-up Duration

Studies conducted on the active ingredient in Calmiox primarily focus on short-term symptom patterns, consistent with the product's intended use for temporary, acute conditions. The studies monitored short-term symptom changes, but there is limited information for long-term outcomes. The consistency and durability of the changes measured during the study period are not well characterized over extended periods, meaning that long-term effects are not fully established.

Evidence in Special Populations

Research exploring the evaluation of the active ingredient in certain specific groups is insufficient or limited. The populations included in most of the core short-term clinical trials were predominantly adults and adolescents without significant pre-existing health conditions. Data for certain groups remain insufficient, and research has not extensively explored these populations, such as younger children or individuals with pre-existing, severe skin conditions.

What is Still Uncertain About Calmiox Research

Key limitations include that sample sizes were modest in some trials, and follow-up durations were limited, restricting the ability to understand patterns beyond the immediate acute phase of irritation. The evidence highlights what is known—and what is still uncertain. Evidence quality varies across studies, and findings were mixed in some of the broader systematic reviews, making a cohesive interpretation of all data challenging. The research provides context, but it does not determine whether an individual will respond similarly.

Key Studies & References

  1. Systematic Review: Topical corticosteroids - Systematic review of treatments for atopic eczema (discussing short-term efficacy and safety limitations)
  2. NICE Guidance: Atopic eczema in under 12s: diagnosis and management (relevant for special population/children limitations and general class use)

Frequently Asked Questions (FAQ)

Common questions about Calmiox (FAQ)

Q: Is Calmiox the same kind of medicine as [similar drug name]?

A: Calmiox is classified as a low-potency topical corticosteroid, which means it belongs to a group of medicines that all work similarly to relieve skin irritation. Regulatory information often discusses these products collectively because they share the same pharmacological class and general purpose.

Q: Can Calmiox be taken with basic painkillers like ibuprofen?

A: Regulatory documents suggest that systemic (oral) forms of hydrocortisone may interact with common nonprescription pain medicines, such as ibuprofen. While the risk is generally low with proper topical application, any potential interaction is related to the amount of the drug absorbed into the bloodstream. Information emphasizes the importance of discussing all medications with a healthcare professional.

Q: Is Calmiox safe to take if I have liver problems?

A: Official product information indicates that patients with severe hepatic impairment (liver problems) are considered to be at an increased risk of systemic absorption. This heightened absorption may lead to adverse effects like HPA axis suppression. Regulatory information indicates that use in this population may necessitate close monitoring by a healthcare provider.

Q: What's the difference between Calmiox and an over-the-counter supplement?

A: Calmiox contains Hydrocortisone, a synthetic glucocorticoid drug that is regulated as a medicine by health authorities. Unlike supplements, drugs like Calmiox must undergo testing to meet specific standards for safety and efficacy, as supplements are governed by a different set of regulatory standards.

Q: Are there long-term side effects known for Calmiox?

A: Official safety warnings state that long-term or extensive use is associated with potential systemic side effects. These can include permanent skin changes, such as skin thinning or stretch marks, as well as more serious conditions like Cushing syndrome or adrenal insufficiency. Official regulatory guidance emphasizes that the medication should be used only for the recommended duration.

Q: What is the official safety classification of Calmiox?

A: Calmiox is formally classified as a Glucocorticoid within the Corticosteroid class of medicines. Its legal status is generally determined by its strength: low concentrations may be regulated for non-prescription use, while higher strengths require a prescription to mitigate risk.

Q: Why is Calmiox sometimes mentioned alongside other similar drugs?

A: Calmiox is a low-potency topical corticosteroid. Official documents and medical literature often mention it alongside other similar drugs because they belong to the same pharmacological class. This is standard practice for discussing how different drugs in the same group compare in terms of potency and use.

Q: Why is Calmiox a prescription drug?

A: The regulatory status of Calmiox is determined by its concentration and specific form. While some low-strength preparations are available over-the-counter, higher strengths require a prescription. This restriction is in place to manage the risks associated with increased systemic absorption when more potent or extensive use is necessary.

Q: How long do the effects of Calmiox last?

A: The effects of Calmiox are intended to be local and temporary, providing relief at the application site. Official product information indicates a typical recommended application frequency, which suggests the effects are maintained by repeated application as directed by a healthcare professional.

Q: Is Calmiox available as a generic medicine?

A: Yes, the active ingredient in Calmiox, Hydrocortisone, is a widely used and globally recognized compound. Regulatory bodies confirm that hydrocortisone is available from numerous manufacturers as a generic medicine in various pharmaceutical forms and strengths.

Q: What happens if I forget to take Calmiox?

A: General regulatory guidance regarding a missed dose indicates that application should occur as soon as it is remembered. However, if the time for the next scheduled application is near, the missed dose is typically skipped, and the regular schedule is resumed.

Q: Does Calmiox cause any weight gain?

A: Weight gain, particularly around the body’s trunk, is a symptom associated with Cushing syndrome, a serious side effect of high systemic absorption. This systemic absorption is an elevated risk that can occur with the extensive or long-term use of topical corticosteroids.

Q: Can older people use Calmiox?

A: Official documents state that elderly patients are generally considered to be more sensitive to the potential systemic side effects of corticosteroids. This is due to possible changes in drug absorption or metabolism. Therefore, use may be permitted but warrants caution.

Q: Is it normal to feel a bit drowsy when starting Calmiox?

A: Dizziness and sleep disturbances, such as insomnia, are noted side effects that may occur if the hydrocortisone is absorbed systemically. However, the risk of these effects is considered low with proper topical application, which is designed for minimal absorption into the bloodstream.

Q: Why do some people say Calmiox helps with sleep, even though that's not its main use?

A: Calmiox is officially approved for the relief of skin itching and irritation. It is not indicated for sleep issues. Patient reports of improved sleep may be an indirect result of the relief from pruritus (itching), which is a common cause of sleep disturbance.

Q: Does Calmiox have an effect on blood pressure?

A: High blood pressure is recognized as a potential symptom associated with Cushing syndrome. This is a serious side effect that can occur if the medication is absorbed extensively into the body, particularly when used long-term or across large areas of skin.

Q: Are there any specific foods I need to avoid while on Calmiox?

A: There are no commonly documented food restrictions specifically for the topical product. For patients taking oral (systemic) corticosteroids, dietary adjustments, such as sodium restriction, are sometimes advised by healthcare providers.

Q: Does Calmiox interact with alcohol?

A: Systemic forms of hydrocortisone have documented alcohol interactions, but the risk with topical use is generally low due to the minimal systemic absorption. Official information emphasizes that disclosure of alcohol use to a healthcare provider is important.

Q: Is it possible to become dependent on Calmiox?

A: Dependence is linked to the potential risk of developing adrenal insufficiency, specifically if the drug is stopped suddenly after long-term or extensive use. This condition is also associated with the risk of withdrawal symptoms.

Q: How does the body get rid of Calmiox?

A: After being absorbed into the body, the active ingredient is metabolized by specific enzymes, such as 11β-Hydroxysteroid dehydrogenases. Official regulatory pharmacokinetics data states that the drug has an average elimination half-life of approximately 1.5 hours in the body.

Q: Is Calmiox okay for people who have kidney issues?

A: Kidney dysfunction or renal disease is listed in official documents as a potential disease interaction for systemic corticosteroids. For topical use, this may increase the risk of side effects if there is significant systemic absorption.

Q: Can Calmiox be taken with popular antacids or heartburn medicines?

A: Official documents do not commonly list a direct interaction with antacids. However, because systemic hydrocortisone may interact with some stomach-related medicines, official guidance emphasizes the importance of consulting a healthcare provider for any potential effects.

Q: Why are there warnings about driving while taking Calmiox?

A: Warnings are related to the risk of systemic absorption, particularly with high-strength or extensive use. This absorption carries a risk of visual disturbances, such as changes in vision or glare problems, that could potentially affect the ability to drive safely.

Q: Is Calmiox effective for anxiety?

A: Calmiox is officially approved and documented for the local symptomatic relief of minor skin irritations and itching. It is not indicated or approved by regulatory bodies for the treatment of mental health conditions like anxiety.

Q: How soon after stopping Calmiox do the effects wear off?

A: The active ingredient has an elimination half-life of approximately 1.5 hours in the body after absorption. The time it takes for local relief to completely disappear depends on the individual's skin condition and the severity of the symptoms being treated.

Q: What happens if I stop taking Calmiox suddenly?

A: Stopping the medication suddenly after long-term, extensive use can lead to symptoms of adrenal insufficiency. These symptoms, which may include fatigue, loss of appetite, or muscle weakness, are a primary reason for the restriction on duration of use.

Q: Does Calmiox interact with herbal remedies like St. John's Wort?

A: Regulatory information notes the importance of discussing the use of all herbal products and supplements with a healthcare provider. Topical hydrocortisone has the potential to interact with certain herbal remedies, and it is important to disclose this usage to your provider.

Q: Does Calmiox affect my ability to operate machinery?

A: Systemic absorption of the medicine, especially with extensive use, carries a risk of visual disturbances. This includes changes in vision that may impair the ability to safely operate machinery.

Q: Is Calmiox commonly used in other countries?

A: Yes, the active ingredient in Calmiox, hydrocortisone, is a globally recognized medicine. Regulatory status and use are documented by government authorities across the world, including in the European Union and the United States.

Q: Is there a risk of withdrawal symptoms with Calmiox?

A: Yes, the risk of developing withdrawal symptoms is linked to the potential for adrenal insufficiency. This risk occurs if the medication is stopped suddenly after a period of extensive or long-term application beyond the recommended duration.

Q: Can I use Calmiox if I have glaucoma?

A: Glaucoma is listed as a potential adverse effect associated with steroid use. Patients already diagnosed with glaucoma are considered to be at an increased risk of elevated eye pressure following steroid exposure.

Q: What if I experience unusual mood changes while on Calmiox?

A: Mood changes, including depression and anxiety, are recognized symptoms associated with high systemic absorption of the medicine, which may lead to Cushing syndrome. These changes can also be a sign of adrenal insufficiency, particularly with extensive or long-term use.

How should Calmiox be stored and disposed of?

Storage Environment and Container Rules

Calmiox must be stored at Controlled Room Temperature, typically defined as 15 C to 30 C (59 F to 86 F), according to regulatory labeling. It is mandatory to protect the medicine from freezing and excessive heat. The product must be kept in its original container, tightly closed, and stored away from excess moisture and direct light.

Child Safety and Disposal Requirements

For safety, Calmiox must always be stored out of the reach and sight of children. If the product is the topical aerosol foam, the pressurized canister must not be punctured or burned. Unused or expired medicine should not be flushed down the toilet or poured into a drain; official guidance recommends consulting a healthcare professional or utilizing an approved drug take-back program for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Calmiox found in:

A-Z Index: